BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Meeting conducted with Institutional Investors/Research Analysts.16-12-2022
16-12-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance with the provisions of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, please find enclosed Copies of newspaper advertisement published in Financial Express (English Language - All India Edition) and Vijayavani, (Kannada Language - Bengaluru Edition) on December 15, 2022 in regards to the above.15-12-2022
BIOCON LTD. - 532523 - Reminder Letter To Shareholders For Claiming Unclaimed Dividends, Whose Equity Shares Are Liable To Be Transferred To IEPF.
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, please find enclosed the copy of reminder letter dated December 12, 2022 sent to eligible shareholders on December 14, 2022, who have not claimed their dividend for 7 (seven) consecutive years, requesting them to claim the same and avoid transfer of such dividends and shares to the IEPF.15-12-2022
Biocon starts new clinical study to evaluate efficacy of Itolizumab
Biotechnology major Biocon on Wednesday said it has initiated a clinical study in collaboration with Equillium Inc to evaluate efficacy of Itolizumab in patients with Ulcerative Colitis. This is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naive patients with moderate to severely active Ulcerative Colitis (UC), Biocon said in a statement. Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialised in handling UC cases, it added. The first patient who intended to participate in the study was screened on December 1, 2022, the company said. "The commencement of the Phase two clinical study, that will determine its efficacy for the treatment of Ulcerative Colitis, is an important step forward in our efforts to bring its benefit to patients15-12-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sir/Madam, Please find enclosed the press release titled 'Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India'. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge.14-12-2022
BIOCON LTD. - 532523 - Appointment Of Independent Director
Appointment of Mr. Peter Bains as an Additional Director is effective from today i.e. December 12, 2022. Further, the appointment of Mr. Peter Bains as an Independent Director shall commence from December 12, 2022, till the conclusion of 48th Annual General Meeting proposed to be held in the year 2026, subject to approval of the shareholders of the Company.12-12-2022
Podcast: Will Viatris deal inject fresh momentum into Biocon biz?
Sohini Das caught up with Biocon Biologics CEO Shreehas Tambe to know more about the deal and the company's future plans09-12-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Meeting conducted with Institutional Investors/Research Analysts.08-12-2022
Biocon Biologics elevates Shreehas Tambe as managing director, CEO
Biocon Biologics on Monday said it has elevated Shreehas Tambe as Managing Director and CEO of the company with immediate effect. Tambe was Deputy CEO of Biocon Biologics, a subsidiary of Bengaluru-based Biocon. He takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said in a statement. Shreehas is taking on the responsibility of leading Biocon Biologics as MD & CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition, Biocon & Biocon Biologics Executive Chairperson Kiran Mazumdar-Shaw said. Shreehas will be aided by a highly experienced executive leadership team in building a future-ready, world leading biosimilars player and a well-recognised global brand that is committed to impacting global healthcare, she added. Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.05-12-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed the press release titled 'Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited' The above information will also be available on the website of the Company at www.biocon.com.05-12-2022